Market closed
Janux Therapeutics/$JANX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Ticker
$JANX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
76
Website
JANX Metrics
BasicAdvanced
$2.3B
-
-$1.19
3.52
-
Price and volume
Market cap
$2.3B
Beta
3.52
52-week high
$65.60
52-week low
$7.79
Average daily volume
1.2M
Financial strength
Current ratio
38.801
Quick ratio
38.577
Long term debt to equity
3.314
Total debt to equity
3.571
Management effectiveness
Return on assets (TTM)
-9.93%
Return on equity (TTM)
-12.05%
Valuation
Price to revenue (TTM)
159.822
Price to book
3.25
Price to tangible book (TTM)
3.25
Price to free cash flow (TTM)
-55.14
Growth
Revenue change (TTM)
54.12%
Earnings per share change (TTM)
-19.06%
3-year revenue growth (CAGR)
86.21%
3-year earnings per share growth (CAGR)
-8.67%
What the Analysts think about JANX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Janux Therapeutics stock.
JANX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
JANX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
JANX News
AllArticlesVideos
Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data
Seeking Alpha·2 weeks ago
Best-Performing Stocks Of 2024
Seeking Alpha·3 weeks ago
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Janux Therapeutics stock?
Janux Therapeutics (JANX) has a market cap of $2.3B as of January 22, 2025.
What is the P/E ratio for Janux Therapeutics stock?
The price to earnings (P/E) ratio for Janux Therapeutics (JANX) stock is 0 as of January 22, 2025.
Does Janux Therapeutics stock pay dividends?
No, Janux Therapeutics (JANX) stock does not pay dividends to its shareholders as of January 22, 2025.
When is the next Janux Therapeutics dividend payment date?
Janux Therapeutics (JANX) stock does not pay dividends to its shareholders.
What is the beta indicator for Janux Therapeutics?
Janux Therapeutics (JANX) has a beta rating of 3.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.